Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages.

Babicky ML, Harper MM, Chakedis J, Cazes A, Mose ES, Jaquish DV, French RP, Childers B, Alakus H, Schmid MC, Foubert P, Miyamoto J, Holman PJ, Walterscheid ZJ, Tang CM, Varki N, Sicklick JK, Messer K, Varner JA, Waltz SE, Lowy AM.

Oncogene. 2019 Jul;38(28):5599-5611. doi: 10.1038/s41388-019-0811-9. Epub 2019 Apr 9.

2.

Therapeutic Considerations for Ron Receptor Expression in Prostate Cancer.

Brown NE, Sullivan C, Waltz SE.

EMS Cancer Sci J. 2018;1(1). pii: 003. Epub 2018 Jul 30.

3.

The BRUCE-ATR Signaling Axis Is Required for Accurate DNA Replication and Suppression of Liver Cancer Development.

Ge C, Vilfranc CL, Che L, Pandita RK, Hambarde S, Andreassen PR, Niu L, Olowokure O, Shah S, Waltz SE, Zou L, Wang J, Pandita TK, Du C.

Hepatology. 2019 Jun;69(6):2608-2622. doi: 10.1002/hep.30529. Epub 2019 Mar 13.

PMID:
30693543
4.

Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation.

Brown NE, Paluch AM, Nashu MA, Komurov K, Waltz SE.

Neoplasia. 2018 Sep;20(9):917-929. doi: 10.1016/j.neo.2018.07.003. Epub 2018 Aug 15.

5.

Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy.

Zhou Z, Jafari M, Sriram V, Kim J, Lee JY, Ruiz-Torres SJ, Waltz SE.

Mol Pharm. 2017 Dec 4;14(12):4551-4559. doi: 10.1021/acs.molpharmaceut.7b00669. Epub 2017 Nov 7.

6.

HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling.

Ruiz-Torres SJ, Benight NM, Karns RA, Lower EE, Guan JL, Waltz SE.

Oncotarget. 2017 Jul 22;8(35):58918-58933. doi: 10.18632/oncotarget.19441. eCollection 2017 Aug 29.

7.

Maternal diethylhexyl phthalate exposure affects adiposity and insulin tolerance in offspring in a PCNA-dependent manner.

Hunt BG, Wang YL, Chen MS, Wang SC, Waltz SE.

Environ Res. 2017 Nov;159:588-594. doi: 10.1016/j.envres.2017.09.004. Epub 2017 Sep 12.

8.

Sequential delivery of erlotinib and doxorubicin for enhanced triple negative Breast cancer treatment using polymeric nanoparticle.

Zhou Z, Kennell C, Jafari M, Lee JY, Ruiz-Torres SJ, Waltz SE, Lee JH.

Int J Pharm. 2017 Sep 15;530(1-2):300-307. doi: 10.1016/j.ijpharm.2017.07.085. Epub 2017 Aug 1.

9.

RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis.

Andrade K, Fornetti J, Zhao L, Miller SC, Randall RL, Anderson N, Waltz SE, McHale M, Welm AL.

Sci Transl Med. 2017 Jan 25;9(374). pii: eaai9338. doi: 10.1126/scitranslmed.aai9338.

10.
11.

HGFL supports mammary tumorigenesis by enhancing tumor cell intrinsic survival and influencing macrophage and T-cell responses.

Benight NM, Wagh PK, Zinser GM, Peace BE, Stuart WD, Vasiliauskas J, Pathrose P, Starnes SL, Waltz SE.

Oncotarget. 2015 Jul 10;6(19):17445-61.

12.

Loss of Ron receptor signaling leads to reduced obesity, diabetic phenotypes and hepatic steatosis in response to high-fat diet in mice.

Stuart WD, Brown NE, Paluch AM, Waltz SE.

Am J Physiol Endocrinol Metab. 2015 Apr 1;308(7):E562-72. doi: 10.1152/ajpendo.00467.2014. Epub 2015 Feb 3.

13.

Loss of vitamin D receptor signaling from the mammary epithelium or adipose tissue alters pubertal glandular development.

Johnson AL, Zinser GM, Waltz SE.

Am J Physiol Endocrinol Metab. 2014 Oct 15;307(8):E674-85. doi: 10.1152/ajpendo.00200.2014. Epub 2014 Aug 19.

14.

Hepatocyte growth factor-like protein is a positive regulator of early mammary gland ductal morphogenesis.

Gurusamy D, Ruiz-Torres SJ, Johnson AL, Smith DA, Waltz SE.

Mech Dev. 2014 Aug;133:11-22. doi: 10.1016/j.mod.2014.07.002. Epub 2014 Jul 15.

15.

Hepatocyte growth factor-like protein is required for prostate tumor growth in the TRAMP mouse model.

Vasiliauskas J, Nashu MA, Pathrose P, Starnes SL, Waltz SE.

Oncotarget. 2014 Jul 30;5(14):5547-58.

16.

The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.

Privette Vinnedge LM, Benight NM, Wagh PK, Pease NA, Nashu MA, Serrano-Lopez J, Adams AK, Cancelas JA, Waltz SE, Wells SI.

Oncogene. 2015 Apr 30;34(18):2325-36. doi: 10.1038/onc.2014.173. Epub 2014 Jun 23.

17.

Ron receptor-dependent gene regulation of Kupffer cells during endotoxemia.

Kulkarni RM, Stuart WD, Waltz SE.

Hepatobiliary Pancreat Dis Int. 2014 Jun;13(3):281-92.

18.

Ron receptor signaling is protective against DSS-induced colitis in mice.

Kulkarni RM, Stuart WD, Gurusamy D, Waltz SE.

Am J Physiol Gastrointest Liver Physiol. 2014 Jun 15;306(12):G1065-74. doi: 10.1152/ajpgi.00421.2013. Epub 2014 Apr 17.

19.

Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.

Cai Y, Balli D, Ustiyan V, Fulford L, Hiller A, Misetic V, Zhang Y, Paluch AM, Waltz SE, Kasper S, Kalin TV.

J Biol Chem. 2013 Aug 2;288(31):22527-41. doi: 10.1074/jbc.M113.455089. Epub 2013 Jun 17.

20.

Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity.

Eyob H, Ekiz HA, Derose YS, Waltz SE, Williams MA, Welm AL.

Cancer Discov. 2013 Jul;3(7):751-60. doi: 10.1158/2159-8290.CD-12-0480. Epub 2013 Apr 23.

21.

The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer.

Zhao H, Chen MS, Lo YH, Waltz SE, Wang J, Ho PC, Vasiliauskas J, Plattner R, Wang YL, Wang SC.

Oncogene. 2014 Mar 13;33(11):1429-37. doi: 10.1038/onc.2013.84. Epub 2013 Apr 1.

22.

Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth.

Gurusamy D, Gray JK, Pathrose P, Kulkarni RM, Finkleman FD, Waltz SE.

Cancer Res. 2013 Mar 15;73(6):1752-63. doi: 10.1158/0008-5472.CAN-12-2474. Epub 2013 Jan 17.

23.

Ron receptor-dependent gene regulation in a mouse model of endotoxin-induced acute liver failure.

Kulkarni RM, Kutcher LW, Stuart WD, Carson DJ, Leonis MA, Waltz SE.

Hepatobiliary Pancreat Dis Int. 2012 Aug 15;11(4):383-92.

24.

Ron receptor tyrosine kinase signaling as a therapeutic target.

Benight NM, Waltz SE.

Expert Opin Ther Targets. 2012 Sep;16(9):921-31. doi: 10.1517/14728222.2012.710200. Epub 2012 Jul 26. Review.

25.

Macrophage-stimulating protein and calcium homeostasis in zebrafish.

Huitema LF, Renn J, Logister I, Gray JK, Waltz SE, Flik G, Schulte-Merker S.

FASEB J. 2012 Oct;26(10):4092-101. doi: 10.1096/fj.11-202663. Epub 2012 Jul 11.

26.

Conditional deletion of β-catenin in mammary epithelial cells of Ron receptor, Mst1r, overexpressing mice alters mammary tumorigenesis.

Wagh PK, Zinser GM, Gray JK, Shrestha A, Waltz SE.

Endocrinology. 2012 Jun;153(6):2735-46. doi: 10.1210/en.2011-1543. Epub 2012 Apr 2.

27.

Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice.

Marshall AM, McClaine RJ, Gurusamy D, Gray JK, Lewnard KE, Khan SA, Waltz SE.

Mol Cancer. 2012 Jan 6;11:2. doi: 10.1186/1476-4598-11-2.

28.

Ron receptor overexpression in the murine prostate induces prostate intraepithelial neoplasia.

Gray JK, Paluch AM, Stuart WD, Waltz SE.

Cancer Lett. 2012 Jan 1;314(1):92-101. doi: 10.1016/j.canlet.2011.09.021. Epub 2011 Sep 24.

29.

The Ron receptor promotes prostate tumor growth in the TRAMP mouse model.

Thobe MN, Gray JK, Gurusamy D, Paluch AM, Wagh PK, Pathrose P, Lentsch AB, Waltz SE.

Oncogene. 2011 Dec 15;30(50):4990-8. doi: 10.1038/onc.2011.205. Epub 2011 May 30.

30.

Ron receptor regulates Kupffer cell-dependent cytokine production and hepatocyte survival following endotoxin exposure in mice.

Stuart WD, Kulkarni RM, Gray JK, Vasiliauskas J, Leonis MA, Waltz SE.

Hepatology. 2011 May;53(5):1618-28. doi: 10.1002/hep.24239.

31.

β-Catenin is required for Ron receptor-induced mammary tumorigenesis.

Wagh PK, Gray JK, Zinser GM, Vasiliauskas J, James L, Monga SP, Waltz SE.

Oncogene. 2011 Aug 25;30(34):3694-704. doi: 10.1038/onc.2011.86. Epub 2011 Mar 21.

32.

The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.

Privette Vinnedge LM, McClaine R, Wagh PK, Wikenheiser-Brokamp KA, Waltz SE, Wells SI.

Oncogene. 2011 Jun 16;30(24):2741-52. doi: 10.1038/onc.2011.2. Epub 2011 Feb 14.

33.

Age-related changes in the epithelial and stromal compartments of the mammary gland in normocalcemic mice lacking the vitamin D3 receptor.

Welsh J, Zinser LN, Mianecki-Morton L, Martin J, Waltz SE, James H, Zinser GM.

PLoS One. 2011 Jan 26;6(1):e16479. doi: 10.1371/journal.pone.0016479.

34.

Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth.

Zhao H, Lo YH, Ma L, Waltz SE, Gray JK, Hung MC, Wang SC.

Mol Cancer Ther. 2011 Jan;10(1):29-36. doi: 10.1158/1535-7163.MCT-10-0778.

35.

Ron receptor deficient alveolar myeloid cells exacerbate LPS-induced acute lung injury in the murine lung.

Nikolaidis NM, Kulkarni RM, Gray JK, Collins MH, Waltz SE.

Innate Immun. 2011 Dec;17(6):499-507. doi: 10.1177/1753425910383725. Epub 2010 Nov 18.

36.

Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.

McClaine RJ, Marshall AM, Wagh PK, Waltz SE.

Neoplasia. 2010 Aug;12(8):650-8.

37.

Chk2*1100delC Acts in synergy with the Ron receptor tyrosine kinase to accelerate mammary tumorigenesis in mice.

Meyer SE, Peace BE, Bahassi el M, Kavanaugh GM, Wagh PK, Robbins SB, Yin M, Wells SI, Zinser GM, Stambrook PJ, Waltz SE.

Cancer Lett. 2010 Oct 28;296(2):186-93. doi: 10.1016/j.canlet.2010.04.011.

38.

Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.

Zhao H, Ou-Yang F, Chen IF, Hou MF, Yuan SS, Chang HL, Lee YC, Plattner R, Waltz SE, Ho SM, Sims J, Wang SC.

Neoplasia. 2010 Mar;12(3):214-23.

39.

Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers.

Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, French R, Stuart W, McClaine R, Aronow B, Hoffman RM, Waltz SE, Lowy AM.

Cancer Res. 2010 Feb 1;70(3):1130-40. doi: 10.1158/0008-5472.CAN-09-0761. Epub 2010 Jan 26.

40.

The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells.

Thobe MN, Gurusamy D, Pathrose P, Waltz SE.

Oncogene. 2010 Jan 14;29(2):214-26. doi: 10.1038/onc.2009.331. Epub 2009 Oct 19.

41.

The Ron receptor tyrosine kinase negatively regulates mammary gland branching morphogenesis.

Meyer SE, Zinser GM, Stuart WD, Pathrose P, Waltz SE.

Dev Biol. 2009 Sep 1;333(1):173-85. doi: 10.1016/j.ydbio.2009.06.028. Epub 2009 Jul 1.

42.

Ron receptor tyrosine kinase negatively regulates TNFalpha production in alveolar macrophages by inhibiting NF-kappaB activity and Adam17 production.

Nikolaidis NM, Gray JK, Gurusamy D, Fox W, Stuart WD, Huber N, Waltz SE.

Shock. 2010 Feb;33(2):197-204. doi: 10.1097/SHK.0b013e3181ae8155.

43.

The Ron receptor tyrosine kinase is not required for adenoma formation in Apc(Min/+) mice.

Meyer SE, Waltz SE, Goss KH.

Mol Carcinog. 2009 Nov;48(11):995-1004. doi: 10.1002/mc.20551.

44.

Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Wagh PK, Peace BE, Waltz SE.

Adv Cancer Res. 2008;100:1-33. doi: 10.1016/S0065-230X(08)00001-8. Review.

45.

Ron receptor tyrosine kinase-dependent hepatic neutrophil recruitment and survival benefit in a murine model of bacterial peritonitis.

Caldwell CC, Martignoni A, Leonis MA, Ondiveeran HK, Fox-Robichaud AE, Waltz SE.

Crit Care Med. 2008 May;36(5):1585-93. doi: 10.1097/CCM.0b013e318170a8c2.

46.

Ron-receptor tyrosine kinase in tumorigenesis and metastasis.

Leonis MA, Thobe MN, Waltz SE.

Future Oncol. 2007 Aug;3(4):441-8. Review.

47.

The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.

Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, Waltz SE, Lowy AM.

Cancer Res. 2007 Jul 1;67(13):6075-82.

48.

The Ron receptor tyrosine kinase regulates acute lung injury and suppresses nuclear factor kappaB activation.

Lentsch AB, Pathrose P, Kader S, Kuboki S, Collins MH, Waltz SE.

Shock. 2007 Mar;27(3):274-80.

49.

Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation.

Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, Peace BE, Beauman SR, Collins MH, Waltz SE.

Cancer Res. 2006 Dec 15;66(24):11967-74.

50.

Homozygous K5Cre transgenic mice have wavy hair and accelerated malignant progression in a murine model of skin carcinogenesis.

Chan EL, Peace BE, Toney K, Kader SA, Pathrose P, Collins MH, Waltz SE.

Mol Carcinog. 2007 Jan;46(1):49-59.

PMID:
17013830

Supplemental Content

Loading ...
Support Center